TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05275907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate
Description: 10 mg capsule once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate
Description: 10 mg capsule once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: 25mg capsule once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: 25mg capsule once daily for 6 weeks
Study: NCT06149780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients treated with laser
Description: Patients treated with laser with topical steroid Patients treated with laser with vehicle
Study: NCT05259982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital root resection
Description: Vital resection of root with attachment loss exceeding 2/3 of the root with the use of calcium silicate cement in the pulpal wound
Study: NCT06063200

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate Pill
Description: Single encapsulated pill

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate Pill
Description: Single encapsulated pill
Study: NCT06179771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA 380
Description: HA380 hemoperfusion cartridge is filled with neutral macroporous resin, mainly adsorbing molecules from 10 to 60 kDa. Because of the accurate 3D macroporous structure and over 54000 m2 adsorption surface area of the resin. The cartridge is attached to the extracorporeal circuit in series with the oxygenator/ filter of the extracorporeal circuit.
Study: NCT05332158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires to report barriers to medication adherence
Description: One questionnaire specific to DOACs and one specific to statins have been integrated within the medical records system and will be sent to eligible patients to respond to following written informed consent.
Study: NCT05266235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation of the Withings bodyscan scale WBS08
Description: Participants will undergo simultaneous recordings of ECGs with the comparator and the study device
Study: NCT05492929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The deep breathing group
Description: The deep breathing group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing technique
Description: 4-7-8 breathing technique Group
Study: NCT05712044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 5 MG
Description: Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 5 MG
Description: Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
Study: NCT04710342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapBuster
Description: Evaluate the safety and effectiveness of the CapBuster System in crossing de novo or restenotic chronic total occlusions in infrapopliteal peripheral arteries.
Study: NCT03678480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 capsules, 250mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: UDCA capsules, 125mg
Study: NCT05186207

Intervention type: OTHER
Intervention: abnormal pre-pregnancy test results that need clinical intervention
Description: The patients who need clinical intervention before or after pregnancy were divided into observation group. Doctors will formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process.
Study: NCT05459831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QDot Micro Catheter
Description: Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QDot Micro Catheter
Description: Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
Study: NCT04210609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaporous Hyperoxia Therapy
Description: 55 minutes of treatment, 2 times per week
Study: NCT05748093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.
Study: NCT05661773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the combined use of vacuum assisted suction and heat exchanger warming
Description: Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
Study: NCT06471868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-HCR21
Description: Betanechol 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-HCR21
Description: Betanechol 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-MIC
Description: Betanechol 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IY-MIC
Description: Betanechol 25mg
Study: NCT04002011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of \[2.0-3.0\]. Other anticoagulants will be not administrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
Study: NCT05766995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterpik Water Flosser
Description: A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral-B Water Flosser
Description: A water flosser and specialized tip that delivers water with microbubbles of air

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Waxed Dental Floss
Description: Nylon string used to clean between the teeth manually
Study: NCT05796635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herpecin L
Description: Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).
Study: NCT06372964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone administered orally, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally, once daily.
Study: NCT06353451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Detox
Description: In the intervention group, smartphone screen time will be reduced to less than 2 hours for 3 consecutive weeks.
Study: NCT05571787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: 700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: 700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: 700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: 700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
Study: NCT05453331

Intervention type: PROCEDURE
Intervention: bilateral STN deep brain stimulation
Description: bilateral deep brain stimulation of the subthalamic nucleus in people with Parkinson's disease

Intervention type: PROCEDURE
Intervention: bilateral STN deep brain stimulation
Description: bilateral deep brain stimulation of the subthalamic nucleus in people with Parkinson's disease
Study: NCT05195008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB113-Matching Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB113-Matching Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11^C]BIO-1819578
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11^C]BIO-1819578
Description: Administered as specified in the treatment arm.
Study: NCT06247709

Intervention type: OTHER
Intervention: Immunohistochemical expression in pitNET cells of KLHL14
Description: Lab essay evaluating the expression of KLHL 14
Study: NCT05754840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-001
Description: High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-005
Description: Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-009
Description: Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
Study: NCT06377826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercises
Description: group A will receive aerobic training like walking and cycling for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: this group will receive resistance training like gluteal bridge, calf raise, squats, seated shoulder press for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medication
Description: This group will be just on medication and no exercise will be given to this group
Study: NCT05526833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
Study: NCT06098235

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Diet advice
Description: The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.
Study: NCT06770179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positional recruitment maneuver
Description: In the third group, in addition to the fixed PEEP, a recruitment maneuver will be performed at the end of the surgery before extubation. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, with 3 breaths in the right lateral decubitus position and 3 breaths in the left lateral decubitus position
Study: NCT06773455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tralokinumab
Description: 600mg at week 0 followed by 300mg Q2W for 24 weeks
Study: NCT06098235

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ORIENT diet intervention
Description: The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
Study: NCT06264895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: three times weekly exercise intervention with protein supplementation
Study: NCT06378814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Caries Removal (No Pulp Exposure)
Description: Caries excavation technique where clinician leaves carious tissue so close to pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Selective Caries Removal (No Pulp exposure)
Description: Complete caries removal even in areas so close to pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy (Pulp Exposed)
Description: In caes of Pulp exposure Amputation of inflamed coronal pulp and capping of remaining vital tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy (Pulp Exposed)
Description: In caes of Pulp exposure Amputation of inflamed coronal pulp and capping of remaining vital tissue
Study: NCT04853784

Intervention type: PROCEDURE
Intervention: intracorporeal anastomosis
Description: intracorporeal anastomosis

Intervention type: PROCEDURE
Intervention: intracorporeal anastomosis
Description: intracorporeal anastomosis
Study: NCT04962360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula
Description: Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (Powder added to water) without added vitamins and minerals
Study: NCT05712512

Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental assessment
Description: individual behavioral and socio-communicative assessment from 6 to 36 months

Intervention type: OTHER
Intervention: Electrophysiological and eyetracking recordings
Description: Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
Study: NCT05173454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education and Support
Description: The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
Study: NCT06333509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT071
Description: a single CAR-T infusion of CT071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT071
Description: a single CAR-T infusion of CT071
Study: NCT05837637

Intervention type: DIAGNOSTIC_TEST
Intervention: The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)
Description: * The VSIT: Odorants used in the VSIT are odorous liquids commercially available in Vietnam. Cotton buds are dipped in diluted odor solution and are used as test materials. The cotton swab is then packaged in a sterile and non-volatile sachet. Participants tore the cotton swab-containing sachet in the direction of the arrow to reveal the bud of the cotton swab and place it approximately 2 cm from the nostrils for 2-3 seconds. The score based on the number of correct answers ranges from 0 to 12.~* The BSIT: BSIT will be purchased from Sensoics, Inc. and used according to the manufacturer's instructions. Odorants are microencapsulated on the paper and odors are released when the subject uses a pencil to scratch the microcapsule coating. Odorants are placed 2 cm from the both nostrils and participants selected the smell from the answer card containing four options for each odorant. The score based on the number of correct answers ranges from 0 to 12

Intervention type: DIAGNOSTIC_TEST
Intervention: The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)
Description: * The VSIT: Odorants used in the VSIT are odorous liquids commercially available in Vietnam. Cotton buds are dipped in diluted odor solution and are used as test materials. The cotton swab is then packaged in a sterile and non-volatile sachet. Participants tore the cotton swab-containing sachet in the direction of the arrow to reveal the bud of the cotton swab and place it approximately 2 cm from the nostrils for 2-3 seconds. The score based on the number of correct answers ranges from 0 to 12.~* The BSIT: BSIT will be purchased from Sensoics, Inc. and used according to the manufacturer's instructions. Odorants are microencapsulated on the paper and odors are released when the subject uses a pencil to scratch the microcapsule coating. Odorants are placed 2 cm from the both nostrils and participants selected the smell from the answer card containing four options for each odorant. The score based on the number of correct answers ranges from 0 to 12
Study: NCT06772532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation A
Description: Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906 - Formulation A
Description: Formulation A
Study: NCT05051774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1. Education
Description: Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2. Exercise
Description: The exercise intervention comprised of two elements as follows:~1. Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~2. Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3. Telephone follow-up
Description: A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
Study: NCT04780620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Intervention Group
Description: Parents will be involved in 8 weekly sessions.